Each Opioid Peptide Modulates Different Pain Phases at Different Spinal Levels
Endogenous opioid peptides showed phase-specific and level-specific pain modulation in the formalin test: beta-endorphin acted supraspinally on acute pain, enkephalins spinally on inflammatory pain, and dynorphin contributed at both levels.
Quick Facts
What This Study Found
Phase- and level-specific pain modulation: beta-endorphin supraspinal/early phase; enkephalins spinal/late phase; dynorphin both levels/both phases — the most detailed mapping of endogenous opioid pain control organization.
Key Numbers
How They Did This
Animal study using ICV and intrathecal injection of selective opioid antisera and receptor antagonists in mice before formalin testing. Both early (acute) and late (inflammatory) pain phases measured at both supraspinal and spinal levels.
Why This Research Matters
This is the most comprehensive mapping of which opioid peptide does what, where, for which type of pain. It provides a complete blueprint for targeted analgesic development.
The Bigger Picture
The opioid pain control system is precisely organized — different peptides, different receptors, different levels, different pain types. This organization enables the most precise analgesic targeting yet conceived.
What This Study Doesn't Tell Us
Mouse formalin test model. Antibody specificity and completeness of blocking are limitations. Acute test may not predict chronic pain organization.
Questions This Raises
- ?Can this detailed map guide selection of opioid drugs by pain type and location?
- ?Does the organization change in chronic pain states?
- ?Could multi-level targeted opioid therapy provide superior analgesia?
Trust & Context
- Key Stat:
- Precision pain map Each opioid peptide handles specific pain types at specific spinal levels — the most detailed blueprint for targeted pain treatment design
- Evidence Grade:
- Preliminary but comprehensive animal evidence with dual-level testing providing the most complete endogenous opioid pain modulation map available.
- Study Age:
- Published in 2002. This mapping has informed targeted analgesic approaches including level-specific drug delivery strategies.
- Original Title:
- Roles of endogenous opioid peptides in modulation of nocifensive response to formalin.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 300(2), 647-54 (2002)
- Authors:
- Wu, Hsiang-En(5), Hung, Kuei-Chun, Mizoguchi, Hirokazu(4), Nagase, Hiroshi, Tseng, Leon F
- Database ID:
- RPEP-00784
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Is there a map of the body's pain control?
Yes — this study provides the most detailed one. Beta-endorphin controls acute pain from the brain, enkephalins control inflammatory pain from the spinal cord, and dynorphin contributes to both types at both levels.
How does this help design better painkillers?
By knowing exactly which opioid system handles which pain type at which level, doctors could choose drugs targeting the specific pathway relevant to each patient's pain — maximizing relief while minimizing side effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00784APA
Wu, Hsiang-En; Hung, Kuei-Chun; Mizoguchi, Hirokazu; Nagase, Hiroshi; Tseng, Leon F. (2002). Roles of endogenous opioid peptides in modulation of nocifensive response to formalin.. The Journal of pharmacology and experimental therapeutics, 300(2), 647-54.
MLA
Wu, Hsiang-En, et al. "Roles of endogenous opioid peptides in modulation of nocifensive response to formalin.." The Journal of pharmacology and experimental therapeutics, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Roles of endogenous opioid peptides in modulation of nocifen..." RPEP-00784. Retrieved from https://rethinkpeptides.com/research/wu-2002-roles-of-endogenous-opioid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.